WO2002060875A8 - Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes - Google Patents

Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes

Info

Publication number
WO2002060875A8
WO2002060875A8 PCT/IB2001/002341 IB0102341W WO02060875A8 WO 2002060875 A8 WO2002060875 A8 WO 2002060875A8 IB 0102341 W IB0102341 W IB 0102341W WO 02060875 A8 WO02060875 A8 WO 02060875A8
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
inhibitors
nicotinamide
derivatives useful
biaryl derivatives
Prior art date
Application number
PCT/IB2001/002341
Other languages
French (fr)
Other versions
WO2002060875A1 (en
Inventor
Robert James Chambers
Thomas Victor Magee
Anthony Marfat
Original Assignee
Pfizer Prod Inc
Robert James Chambers
Thomas Victor Magee
Anthony Marfat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK879-2003A priority Critical patent/SK8792003A3/en
Priority to MXPA03006887A priority patent/MXPA03006887A/en
Application filed by Pfizer Prod Inc, Robert James Chambers, Thomas Victor Magee, Anthony Marfat filed Critical Pfizer Prod Inc
Priority to HU0400637A priority patent/HUP0400637A2/en
Priority to JP2002561026A priority patent/JP2004520386A/en
Priority to EA200300621A priority patent/EA200300621A1/en
Priority to IL15641301A priority patent/IL156413A0/en
Priority to CA002436535A priority patent/CA2436535A1/en
Priority to EEP200300360A priority patent/EE200300360A/en
Priority to PL01364135A priority patent/PL364135A1/en
Priority to BR0116852-5A priority patent/BR0116852A/en
Priority to EP01273556A priority patent/EP1355884A1/en
Priority to KR10-2003-7010074A priority patent/KR20030074761A/en
Priority to NZ526453A priority patent/NZ526453A/en
Publication of WO2002060875A1 publication Critical patent/WO2002060875A1/en
Priority to IS6846A priority patent/IS6846A/en
Priority to BG108038A priority patent/BG108038A/en
Priority to NO20033397A priority patent/NO20033397L/en
Publication of WO2002060875A8 publication Critical patent/WO2002060875A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of the formula (I): where j is 0 or 1 provided that when j is 0, n must be 2; k is 0 or 1; m is 0, 1, or 2; n is 1 or 2; W1 is -0-; or -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; W2 is -O-CRARB- or is absent; Y is =C(R1a)- or -[N∊(O)k]- where k is 0 or 1; R?A and RB¿ are -H; -F; -CF¿3?; -(C1-C4)alkyl; -(C3-C7)cycloalkyl; phenyl; or benzyl substituted with 0 to 3 substituents R?10; or RA and RB¿ are taken together, but only in the case where m is 1, to form a spiro moiety; R?C and RD¿ have the same meaning as R?A and RB¿ except that one of them must be -H, R?1 and R2¿ are -H; -F; -Cl; -CN; -NO¿2?; (C1-C4)alkyl; -(C2-C4)alkynal; fluorinated-(C1-C3)alkyl; -OR?16¿; and -C(=O)NR22aR22b; R3 is -H; -(C¿1?-C3)alkyl; phenyl; benzyl; or -OR?16; R4, R5 and R6¿ in addition to other meanings may be taken together to form, e.g., form (II): Q1, Q2 and Z are as defined in the application.
PCT/IB2001/002341 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes WO2002060875A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
NZ526453A NZ526453A (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
EEP200300360A EE200300360A (en) 2001-01-31 2001-12-06 Biaryl derivatives of nicotinamide used as inhibitors of PDE4 isozymes
HU0400637A HUP0400637A2 (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes and pharmaceutical compositions containing them
JP2002561026A JP2004520386A (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
EA200300621A EA200300621A1 (en) 2001-01-31 2001-12-06 BIARRYLIC DERIVATIVES OF NICOTINAMIDE, USEFUL AS AN INHIBITORS OF PDE4 ISOERMINENTS
IL15641301A IL156413A0 (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
CA002436535A CA2436535A1 (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
SK879-2003A SK8792003A3 (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes and pharmaceutical composition containing them
PL01364135A PL364135A1 (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
EP01273556A EP1355884A1 (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
BR0116852-5A BR0116852A (en) 2001-01-31 2001-12-06 Biarylated nicotinamide derivatives useful as pde4 isozyme inhibitors
KR10-2003-7010074A KR20030074761A (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
MXPA03006887A MXPA03006887A (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes.
IS6846A IS6846A (en) 2001-01-31 2003-06-16 Nicotinamide baryl derivatives useful for inhibiting PDE4 isotopic enzymes
BG108038A BG108038A (en) 2001-01-31 2003-07-28 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
NO20033397A NO20033397L (en) 2001-01-31 2003-07-30 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26549201P 2001-01-31 2001-01-31
US60/265,492 2001-01-31

Publications (2)

Publication Number Publication Date
WO2002060875A1 WO2002060875A1 (en) 2002-08-08
WO2002060875A8 true WO2002060875A8 (en) 2003-07-31

Family

ID=23010671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/002341 WO2002060875A1 (en) 2001-01-31 2001-12-06 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes

Country Status (25)

Country Link
US (2) US6649633B2 (en)
EP (1) EP1355884A1 (en)
JP (1) JP2004520386A (en)
KR (1) KR20030074761A (en)
CN (1) CN1518542A (en)
BG (1) BG108038A (en)
BR (1) BR0116852A (en)
CA (1) CA2436535A1 (en)
CR (1) CR7025A (en)
CZ (1) CZ20031895A3 (en)
EA (1) EA200300621A1 (en)
EC (2) ECSP034710A (en)
EE (1) EE200300360A (en)
HU (1) HUP0400637A2 (en)
IL (1) IL156413A0 (en)
IS (1) IS6846A (en)
MA (1) MA26983A1 (en)
MX (1) MXPA03006887A (en)
NO (1) NO20033397L (en)
NZ (1) NZ526453A (en)
OA (1) OA12540A (en)
PL (1) PL364135A1 (en)
SK (1) SK8792003A3 (en)
WO (1) WO2002060875A1 (en)
ZA (1) ZA200304894B (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
EP1389468A4 (en) * 2001-05-23 2007-01-10 Tanabe Seiyaku Co Compositions for promoting healing of bone fracture
MXPA03010672A (en) * 2001-05-23 2004-03-02 Tanabe Seiyaku Co Therapeutic compositions for repairing chondropathy.
WO2003071870A1 (en) * 2002-02-26 2003-09-04 Schlesinger Stephen L Use of leukotriene receptor antagonist for treatment of scarring
EP1424101A3 (en) * 2002-11-29 2004-08-18 NOZAKI, Masako Use of a leukotriene C4 and D4 receptor antagonist for the preparation of a medicament for treating or preventing brain inflammation and sepsis
JP2006516548A (en) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Drug delivery from rapidly gelled polymer compositions
EP1624893A2 (en) * 2003-04-01 2006-02-15 Applied Research Systems ARS Holding N.V. Inhibitors of phosphodiesterases in infertility
GB0309781D0 (en) * 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
GB0317498D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Compounds
US20050020587A1 (en) * 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
GB0317516D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US7132435B2 (en) * 2003-07-25 2006-11-07 Pfizer Inc. Compounds
US7153870B2 (en) 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0317484D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US20050154006A1 (en) * 2004-01-09 2005-07-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions based on a scopineester and nicotinamide derivatives
WO2006073413A1 (en) * 2004-02-20 2006-07-13 The Board Of Trustees Of The University Of Illinois Blood pressure reduction in salt-sensitive
JP2007528420A (en) * 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド Novel M3 muscarinic acetylcholine receptor antagonist
EP2172222A3 (en) * 2004-04-26 2010-06-23 Ono Pharmaceutical Co., Ltd. Novel BLT2-mediated disease, BLT2-binding agent and compound
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
WO2006070370A2 (en) 2004-12-29 2006-07-06 Hadasit Medical Research Services & Development Limited Stem cells culture systems
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (en) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Regulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010516734A (en) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 3,5-diamino-6- (2,3-dichlorophenyl) -1,2,4-triazine or R (-)-2,4-diamino-5- (2,3-dichlorophenyl) -6-fluoromethylpyrimidine A pharmaceutical composition comprising
EP2147094B2 (en) 2007-04-18 2018-02-21 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2700877T3 (en) * 2009-05-12 2019-02-19 Koninklijke Philips Nv Phosphodiesterase 4D7 as a marker of prostate cancer
KR102110469B1 (en) 2009-05-12 2020-05-14 코닌클리케 필립스 엔.브이. Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer
BR112012004677A2 (en) 2009-09-01 2020-11-03 Catabasis Pharmaceuticals, Inc. niacin fatty acid conjugates and their uses
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
WO2011044141A1 (en) * 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid fibrate derivatives and their uses
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
LT3013796T (en) * 2013-06-27 2020-05-25 Lg Chem, Ltd. Biaryl derivatives as gpr120 agonists
ES2694375T3 (en) * 2013-09-17 2018-12-20 Vectus Biosystems Limited Compositions for the treatment of hypertension and / or fibrosis
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
DK3240892T5 (en) 2014-12-30 2020-10-19 Cell Cure Neurosciences Ltd RPE CELL POPULATIONS AND METHODS FOR EACHING THEM
ES2865024T3 (en) 2015-07-29 2021-10-14 Hadasit Med Res Service Large-scale production of retinal pigment epithelium cells
PL3331994T3 (en) 2015-08-05 2023-01-30 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
AU2016303631B2 (en) 2015-08-05 2022-07-28 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
CA3002919A1 (en) 2015-10-26 2017-05-04 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
US9725406B1 (en) 2016-10-13 2017-08-08 Resolvex Pharmaceuticals Inc. Substituted hydroxystilbenes and their therapeutic applications
JP2020511539A (en) 2017-03-16 2020-04-16 リネージ セル セラピューティクス インコーポレイテッド Method to measure the therapeutic effect of retinal disease treatment
SG11202005795TA (en) 2017-12-29 2020-07-29 Cell Cure Neurosciences Ltd Retinal pigment epithelium cell compositions
EP3787612A4 (en) * 2018-05-04 2021-11-17 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2020058979A2 (en) 2018-09-20 2020-03-26 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral sclerosis
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN111888349B (en) * 2020-07-29 2021-10-22 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 Action of nimbin in preparing medicine for promoting survival of ischemic superlong random skin flap
WO2022261320A1 (en) 2021-06-09 2022-12-15 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
WO2023009676A1 (en) 2021-07-28 2023-02-02 Lineage Cell Therapeutics, Inc. Expansion of retinal pigment epithelium cells
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2140772A5 (en) 1971-06-07 1973-01-19 Aries Robert Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics
US4270946A (en) * 1979-10-01 1981-06-02 Stauffer Chemical Company N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof
US4692185A (en) * 1986-01-13 1987-09-08 Stauffer Chemical Company N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
EP0500989B1 (en) 1991-02-27 1998-12-09 Lacer, S.A. N-(alpha-substituted-pyridinyl) carbonyl dipeptide antihypertensive agents
DE4200323A1 (en) 1992-01-09 1993-07-15 Bayer Ag HERBICIDES AND PLANT NEMICIDES BASED ON MERCAPTONICOTINIC DERIVATIVES
SK279958B6 (en) 1992-04-02 1999-06-11 Smithkline Beecham Corporation Compounds exhibiting anti-allergic and anti-inflammatory properties, pharmaceutical composition them containing and their use
JPH08511805A (en) 1993-06-18 1996-12-10 スミスクライン・ビーチャム・コーポレイション Compound
JP3406689B2 (en) 1994-03-15 2003-05-12 株式会社大塚製薬工場 Naphthyridine and pyridopyrazine derivatives
US5618027A (en) * 1994-07-20 1997-04-08 Nevrekar; Venkatesh R. Gate valve
EP0796096A4 (en) 1994-12-23 1998-04-29 Smithkline Beecham Corp 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
TW429148B (en) * 1995-10-27 2001-04-11 Pfizer Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US5922557A (en) 1997-01-09 1999-07-13 Merck & Co., Inc. System for stably expressing a high-affinity camp phosphodiesterase and use thereof
CA2285548C (en) 1997-04-04 2006-07-11 Pfizer Products Inc. Nicotinamide derivatives
GB9715584D0 (en) * 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
UA67753C2 (en) 1997-10-10 2004-07-15 Смітклайн Бічам Корпорейшн Method for obtaining substituted of cyanocyclohexan acid
AR015966A1 (en) 1997-10-17 2001-05-30 Smithkline Beecham Corp USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT
AR015190A1 (en) 1997-10-23 2001-04-18 Smithkline Beecham Corp A CRYSTALLINE POLYMORPH OF 1,3-DICICLOPROPILMETIL-8-AMINOXANTINA, PROCEDURE FOR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND ITS USING THE MANUFACTURE OF A MEDICINAL PRODUCT
AP2002002590A0 (en) * 2000-01-31 2002-09-30 Pfizer Prod Inc Pyrimidinyl carboxamides useful as inhibitors of PDE4 isozymes.
PL357995A1 (en) * 2000-01-31 2004-08-09 Pfizer Products Inc. Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes

Also Published As

Publication number Publication date
IS6846A (en) 2003-06-16
CA2436535A1 (en) 2002-08-08
JP2004520386A (en) 2004-07-08
SK8792003A3 (en) 2004-09-08
MA26983A1 (en) 2004-12-20
ECSP034710A (en) 2003-09-24
HUP0400637A2 (en) 2004-06-28
US20040048903A1 (en) 2004-03-11
CN1518542A (en) 2004-08-04
MXPA03006887A (en) 2003-11-13
BG108038A (en) 2004-07-30
ZA200304894B (en) 2004-06-24
WO2002060875A1 (en) 2002-08-08
PL364135A1 (en) 2004-12-13
EE200300360A (en) 2003-12-15
CZ20031895A3 (en) 2004-08-18
KR20030074761A (en) 2003-09-19
US6953810B2 (en) 2005-10-11
US6649633B2 (en) 2003-11-18
EA200300621A1 (en) 2003-12-25
US20020193612A1 (en) 2002-12-19
NZ526453A (en) 2005-01-28
IL156413A0 (en) 2004-01-04
OA12540A (en) 2006-06-05
ECSP034709A (en) 2003-09-24
NO20033397L (en) 2003-09-19
EP1355884A1 (en) 2003-10-29
BR0116852A (en) 2004-02-25
NO20033397D0 (en) 2003-07-30
CR7025A (en) 2003-11-25

Similar Documents

Publication Publication Date Title
WO2002060875A8 (en) Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
BG107960A (en) Ether derivatives useful as inhibitors of pde4 isozymes
BG108039A (en) Thiazolyl-, oxazolyl-, pyrrolyl- and amidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
US5760066A (en) Compounds and methods for inhibiting hyper-proliferative cell growth
RU2342365C2 (en) Arylsubstituted pyrazolamides as kinases inhibitors
AP2002002589A0 (en) Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes.
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
WO2004052893A3 (en) Substituted dihydropyrano indole-3,4-dione derivatives and 3-oxoacetic acid substituted 2-hydroxymethylindole derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
NO20043176L (en) Nicotinamide derivatives useful as P38 inhibitors
RU2016115803A (en) SUBSTITUTED NICOTINIMIDE VTK INHIBITORS, THEIR PRODUCTION AND APPLICATION IN TREATMENT OF CANCER, INFLAMMATORY AND AUTOIMMUNE DISEASES
PL1635835T3 (en) 2-aminopyrimidine derivatives as raf kinase inhibitors
NZ531854A (en) Aminobenzamide derivatives as glycogen synthase kinase 3beta inhibitors
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
UA84878C2 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their preparation
JP2013544893A5 (en)
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
RS51949B (en) Kinase inhibitors
WO2007143422A3 (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
SG168409A1 (en) Pyrazole derivatives as phosphodiesterase 4 inhibitors
NO20072753L (en) 3-Ethylidene hydrazino-substituted heterocyclic compounds as thrombopoietin receptor activators
WO2007024600A3 (en) Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
PE20050329A1 (en) NICOTINAMIDE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE PDE4
DK0869945T3 (en) Catechol dietary derivatives useful as pharmaceuticals
EP0314429A3 (en) Fungicidal pyridyl cyclopropane carboxamidines
SE0202461D0 (en) Novel compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 156413

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 526453

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 608/MUMNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002220966

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/04894

Country of ref document: ZA

Ref document number: 200304894

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 200300621

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2001273556

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV2003-1895

Country of ref document: CZ

Ref document number: P20030552A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 8792003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500640

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 10803801

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1200300666

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006887

Country of ref document: MX

Ref document number: 2436535

Country of ref document: CA

Ref document number: 1020037010074

Country of ref document: KR

Ref document number: P-602/03

Country of ref document: YU

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 32/2002 UNDER (71) THE NAME SHOULD READ "PFIZER PRODUCTS INC."

WWE Wipo information: entry into national phase

Ref document number: 5231

Country of ref document: GE

Ref document number: 2002561026

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1020037010074

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018230717

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001273556

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-1895

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 526453

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526453

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020037010074

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2001273556

Country of ref document: EP